Esophageal Squamous Cell Carcinoma Clinical Trials

17 studies are recruiting for esophageal squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

   Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center ( Site 1904), Pittsburgh, Pennsylvania

   Locations

   48 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06780111 on ClinicalTrials.gov

2. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

3. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

4. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

   The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   16 in total

   Run by

   EvolveImmune United, Inc

   See if you can join NCT07217171 on ClinicalTrials.gov

5. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

6. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

   This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who hav…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson, Arizona

   Locations

   58 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05319730 on ClinicalTrials.gov

7. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START-San Antonio, San Antonio, Texas

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

8. A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

   The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (HER2)-negative, programmed death-ligand 1(PD-L1)-positive, un…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Helios Clinical Research, Cerritos, California

   Locations

   8 in total

   Run by

   BeOne Medicines

   See if you can join NCT07554521 on ClinicalTrials.gov

9. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

   This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Hospital, Phoenix, Arizona

   Locations

   132 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06644781 on ClinicalTrials.gov

10. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    62 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

11. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology, Anchorage, Alaska

    Locations

    158 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

12. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Foundation for Medical Education and Research - Mayo Cl, Scottsdale, Arizona

    Locations

    41 in total

    Run by

    Alentis Therapeutics AG

    See if you can join NCT06747585 on ClinicalTrials.gov

13. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

14. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Scottsdale, Arizona

    Locations

    10 in total

    Run by

    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

15. A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

    Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California

    Locations

    7 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT05563766 on ClinicalTrials.gov

16. RAPA-201 Therapy of Solid Tumors

    The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the ad…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hackensack University Medical Center, Hackensack, New Jersey

    Run by

    Rapa Therapeutics LLC

    See if you can join NCT05144698 on ClinicalTrials.gov

17. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov